RETRACTED: Carvedilol alleviates the detrimental effects of azathioprine on hepatic tissues in experimental rats: Focusing on redox system, inflammatory and apoptosis pathways
Human & Experimental Toxicology · 2024
DOI: 10.1177/09603271241269003 ↗Kurz gefasst
Zurückgezogene Publikation in der Zeitschrift Human & Experimental Toxicology, 2024. Verfasst von Abdel-Gawad S Shalkami und 2 weiteren Autor:innen. Beteiligte Einrichtung: Pharmacology and Toxicology Department, Faculty of Pharmacy, Al-Azhar University, Assiut, Egypt. Hauptthemen laut MEDLINE: Carvedilol, Apoptosis, Chemical and Drug Induced Liver Injury, Liver. Die Arbeit wurde bisher 2-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
PURPOSE: Drug-induced liver injury is becoming an increasingly important topic in drug research and clinical practice. Due to a lack of experimental animal models, predicting drug-induced liver injury in humans is challenging. Azathioprine (AZA) is a classical immunosuppressant with hepatotoxic adverse effects. The present study aimed to address the hepatoprotective effect of carvedilol (CAR) against AZA-induced hepatocellular injury via assessing redox-sensitive signals. METHOD: To achieve this purpose, rats were allocated into four groups: control, CAR only, AZA only, and CAR plus AZA groups. The induction of hepatic injury was induced by a single intraperitoneal injection of AZA at a dose of 50 mg/kg on the 6th day of the experiment. Each experimental protocol was approved and supervised by the Ethics Committee for Animal Experiments. RESULTS: The results of the present study revealed that CAR administration significantly diminished AZA-induced hepatic dysfunction, as evidenced by relief of hepatic function biomarkers and histopathological aberration induced by AZA injection. Besides, CAR restored oxidant/antioxidant balance as well as NRF2 expression. In addition, CAR suppressed inflammatory response induced by AZA challenge as evidenced by downregulation of TLR4, TNF-α, MPO, and eNOS/iNOS levels in hepatic tissue. Moreover, CAR recovered apoptotic/anti-apoptotic status by modulation of caspase-3/Bcl2 expression. CONCLUSION: Taken together, CAR protects against AZA-induced hepatic injury via antioxidant, anti-inflammatory, and anti-apoptotic activities. These findings revealed that CAR could be a good candidate for hepatic injury protection and can be added to AZA therapeutic regimen to reduce their adverse effect.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pharmacology and Toxicology Department, Faculty of Pharmacy, Al-Azhar University, Assiut, Egypt.
- Clinical Pharmacy Program, Faculty of Health Science and Nursing, Al-Rayan Colleges, Medina, Saudi Arabia.
- Clinical Pharmacy Department, Faculty of Pharmacy, Al-Azhar University, Assiut, Egypt.
ORCID-Profile: Ehab A M El-Shoura
Zitieren
APA
Shalkami, A. S., El-Shoura, E. A. M., & Hassan, M. I. A. (2024). RETRACTED: Carvedilol alleviates the detrimental effects of azathioprine on hepatic tissues in experimental rats: Focusing on redox system, inflammatory and apoptosis pathways. Human & Experimental Toxicology. https://doi.org/10.1177/09603271241269003
Vancouver
Shalkami AS, El-Shoura EAM, Hassan MIA. RETRACTED: Carvedilol alleviates the detrimental effects of azathioprine on hepatic tissues in experimental rats: Focusing on redox system, inflammatory and apoptosis pathways. Human & Experimental Toxicology. 2024. doi:10.1177/09603271241269003
BibTeX
@article{Shalkami2024,
author = {Shalkami, Abdel-Gawad S and El-Shoura, Ehab A M and Hassan, Mohammed I A},
title = {RETRACTED: Carvedilol alleviates the detrimental effects of azathioprine on hepatic tissues in experimental rats: Focusing on redox system, inflammatory and apoptosis pathways},
journal = {Human & Experimental Toxicology},
year = {2024},
doi = {10.1177/09603271241269003}
}
EUVIMED